Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-stratified Treatment of Sonrotoclax Combined With Chemotherapy in Newly Diagnosed AML
NCT06497062Phase 2Active, not recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonrotoclax in acute myeloid leukemia (AML), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Event-Free Survival at 2 years. Started Oct 2024; status: active, not recruiting.
02
Drugs
sonrotoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06497062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497062.